Biotech Pipelines: Prices Never Lower
Pharmaceutical companies love to deals early, at R&D stage, or late, when products are ready to be marketed. But they hate doing deals in the middle. Why? The risk to too high. Everyone knows what to expect from late stage deals; and no one's going to get killed for an early-stage deal that goes wrong. But Phase I and II deals often carry high price tags and chancy pay-offs.
You may also be interested in...
Manufacturers in the past haven't paid much heed to health plans' half-hearted efforts to reign in biotech drug spending. They figure if the drug is good enough, payers have to cover it. But health plans are for the first time serious about managing specialty pharma spending. Manufacturers should take heed because the impact on their revenues and marketing strategies could be significant.
Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.
The Danish firm’s four key products yielded 31% sales growth in 2022, and the company is investing in the anticipated mid-year launch of an Alzheimer’s agitation indication for Rexulti.